PM Narendra Modi has been administered the second dose of indigenously made COVID vaccine Covaxin at AIIMS-Delhi on April 8. Sharing his vaccination photo on Twitter, PM urged, "If you are eligible for the vaccine, get your shot soon." He had received his first dose of the vaccine on March 1. Reportedly, the Centre has opened the vaccination for everyone aged 45 and above in the third-phase from April 7.
Courtesy: The Times of India
CEO of Serum Institute of India, Adar Poonawalla said if a gap of 2-3 months is kept between the first and second dose then the efficacy of Covishield increases to up to 90%. And if the gap is increased for other vaccines it will yield similar results. In March, India decided to increase the interval between the two shots to 8 weeks on the recommendation by the National Expert Group.
Courtesy: India Today
The Centre, on March 22, directed all states and union territories to increase vaccine dose interval from existing 4-6 weeks to 4-8 weeks. Notably, the recommendation based on the vaccine administration's expert committee is only for the 'Covishield' vaccine and not for 'Covaxin'. The Centre's decision is inspired by scientific evidence that shows protection against coronavirus is enhanced if Covishield's second dose is administered between 6… read-more
Courtesy: Business Standard
The Centre’s Subject Expert Committee has recommended to remove the "clinical trial mode" label from the Bharat Biotech’s COVID-19 vaccine, Covaxin. Reportedly, if the recommendation is considered by the Drugs Controller General of India, it will boost the usage of the vaccine. The recommendation came after Covaxin showed 80.6% efficiency in the late-stage clinical trials. The DCGI’s nod will also not require patients to sign consent form… read-more
Courtesy: The Indian Express
Indian pharmaceutical giant Bharat Biotech has claimed 81% efficacy against COVID-19 for its vaccine 'Covaxin'. Releasing the phase three clinical data of the vaccine on March 3, the company claimed the vaccine of being effective against the UK variants of the virus. While peer reviews are still awaited, the developer conducted clinical trials on over 25,800 people. Reportedly, Indian drug regulator DCGI earlier approved the Covaxin for… read-more
The Centre on March 1 stated CoWIN app has been developed only for administrators to manage the inoculation drive and is not a registration platform for COVID-19 vaccination. It clarified that individuals, who want to get vaccinated, can register themselves through official website. The statement followed the beginning of India's second-phase of mass vaccination which is expected to cover around 27 crore people who are either aged above 60 or… read-more
As per reports, Uttar Pradesh has received the highest number of vaccine shots (21,291) after the launch of nationwide COVID-19 vaccination drive. Andhra Pradesh (18,412), Maharashtra (18,328), and Bihar (18169) followed UP in the list of most vaccinated states. The Union Health Ministry declared that 1,91,181 people were vaccinated in 3,352 vaccination sessions. Currently, the Serum Institute of India's Covishield and Bharat Biotech's… read-more
In a letter addressed to the medical superintendent, the resident doctors of Delhi's Ram Manohar Lohia Hospital have expressed their apprehension towards Bharat Biotech's Covaxin due to inadequate trial. The doctors instead entreated to use the Serum Institute of India's Covishield vaccine. The decision drew criticism as the panel approved just a day after asking Bharat Biotech to provide more evidence. Reportedly, Covaxin is in its Phase-III… read-more
Courtesy: News 18
Covaxin manufacturer Bharat Biotech has promised to compensate vaccine recipients if they experience any adverse effects post-vaccination as mentioned in its consent form. However, the company has advised the recipients to follow Covid-19 norms even after inoculation the vaccine. Reportedly, Centre has ordered a supply of 55 lakh doses of Covaxin considering the vaccine's efficacy which is still under the phase-three of clinical trials.
Courtesy: The Indian Express
Union Health Ministry has not authorised the administration of two recently approved COVID vaccines on children below 18 years of age. Reportedly, a letter from the ministry has cited the comparative factsheet for the vaccines as the reason behind the decision. Earlier, the Drugs Controller General of India (DCGI) has granted approval for the use of the vaccines - Bharat Biotech's 'Covaxin' and Serum Institute of India's 'Covishield' - on… read-more
Courtesy: Times Now